SI
HQL

Stephens Inc’s abrdn Life Sciences Investors HQL Stock Holding History

Stephens Inc’s Portfolio HQL Stock Details HQL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$495K Buy
30,417
+6,548
+27% +$109K 0.01% 853
2025
Q4 		$401K Hold
23,869
– – 0.01% 926
2025
Q3 		$370K Buy
23,869
+2,638
+12% +$36.1K ﹤0.01% 955
2025
Q2 		$272K Buy
21,231
+1,895
+10% +$23.4K ﹤0.01% 1056
2025
Q1 		$245K Buy
19,336
+6,947
+56% +$94.1K ﹤0.01% 1068
2024
Q4 		$163K Sell
12,389
-318
-3% -$4.59K ﹤0.01% 1182
2024
Q3 		$192K Buy
12,707
+896
+8% +$13.6K ﹤0.01% 1200
2024
Q2 		$167K Sell
11,811
-348
-3% -$4.71K ﹤0.01% 1188
2024
Q1 		$166K Sell
12,159
-677
-5% -$9.37K ﹤0.01% 1182
2023
Q4 		$173K Buy
12,836
+1,288
+11% +$15.8K ﹤0.01% 1109
2023
Q3 		$144K Sell
11,548
-95
-0.8% -$1.25K ﹤0.01% 1081
2023
Q2 		$158K Buy
11,643
+236
+2% +$3.26K ﹤0.01% 1097
2023
Q1 		$159K Sell
11,407
-2,518
-18% -$36K ﹤0.01% 1062
2022
Q4 		$198K Sell
13,925
-77,220
-85% -$1.12M ﹤0.01% 1010
2022
Q3 		$1.25M Buy
91,145
+48,168
+112% +$720K 0.03% 475
2022
Q2 		$612K Buy
42,977
+32,549
+312% +$492K 0.01% 659
2022
Q1 		$172K Sell
10,428
-55,139
-84% -$949K ﹤0.01% 1191
2021
Q4 		$1.26M Sell
65,567
-52,416
-44% -$1.05M 0.02% 557
2021
Q3 		$2.45M Buy
117,983
+1,898
+2% +$40.6K 0.04% 413
2021
Q2 		$2.49M Buy
116,085
+99,524
+601% +$2.01M 0.04% 429
2021
Q1 		$326K Buy
16,561
+913
+6% +$18.8K 0.01% 974
2020
Q4 		$309K Buy
15,648
+626
+4% +$11.6K 0.01% 908
2020
Q3 		$264K Buy
15,022
+2,084
+16% +$37.3K 0.01% 929
2020
Q2 		$232K Buy
+12,938
New +$222K 0.01% 919
2019
Q1 		– Sell
-30,061
Closed -$454K – 1192
2018
Q4 		$454K Sell
30,061
-1,182
-4% -$20.8K 0.01% 728
2018
Q3 		$638K Buy
31,243
+7,211
+30% +$143K 0.02% 711
2018
Q2 		$452K Buy
24,032
+731
+3% +$13.8K 0.01% 625
2018
Q1 		$448K Buy
23,301
+10,375
+80% +$208K 0.02% 517
2017
Q4 		$254K Sell
12,926
-55,058
-81% -$1.1M 0.01% 600
2017
Q3 		$1.46M Buy
+67,984
New +$1.44M 0.05% 316

Other funds holding HQL

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
FHA
Flagship Harbor Advisors Boston, Massachusetts $2.27B AUM 18.34% 1-Year Est. Return
Allspring Global Investments
Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Stephens Inc's HQL Position: Q1 2026 in Review

Stephens Inc increased its abrdn Life Sciences Investors (HQL) stake by 27% in Q1 2026, buying an estimated $109K and bringing the position to 30,417 shares worth $495K. The position accounts for 0.01% of the portfolio, ranked #853.

Stephens Inc first reported a position in HQL in Q3 2017 and has held it in 30 quarters since. The position peaked at $2.49M in Q2 2021. 86 funds tracked by Wall St. Rank hold HQL as of Q1 2026.

  • Stephens Inc held 30,417 shares of abrdn Life Sciences Investors worth $495K as of Q1 2026.
  • Stephens Inc bought 6,548 abrdn Life Sciences Investors shares in Q1 2026, an estimated $109K.
  • abrdn Life Sciences Investors made up 0.01% of Stephens Inc's portfolio in Q1 2026, its #853 holding.
  • Stephens Inc first reported a position in abrdn Life Sciences Investors in Q3 2017 and has held it in 30 quarters since.
  • Stephens Inc's abrdn Life Sciences Investors position peaked at $2.49M in Q2 2021.
  • 86 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q1 2026.

Based on Stephens Inc's 13F filing for Q1 2026, filed 28 Apr 2026.